One of the main side-effects of tacrolimus in solid organ transplanted patients is post
transplant diabetes mellitus (PTDM). It is not known if different pharmacokinetic properties
influence the risk of developing PTDM. It is possible that it either is high peak
concentrations of high overall systemic exponation that is responsible for the effect on
insulin secretion. With the new slow-release formulation of tacrolimus (Advagraf) a different
pharmacokinetic profile is introduced to patients and it is of interest to investigate if
this affects insulin secretion and insulin sensitivity of patients.
Hypothesis: The pharmacokinetic profile of tacrolimus affects the insulin secretion in renal
transplant recipients.